Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.
Jeremy M. Pantin, MD
Advertisement
Articles by Jeremy M. Pantin, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer
5